Search Results for 'r-snm'
-
Neurological
FDA Approves Axonics' r-SNM System for 3T Full-Body MRI Scans
The company's sacral neuromodulation (SNM) devices treat urinary and bowel dysfunction.Business Wire 07.02.20
-
Neurological
FDA Approves Axonics' Next-Gen Implantable Neurostimulator
Decreases recharge interval to once a month.Business Wire 04.14.20
-
Axonics Grows Patent Portfolio for its Implantable Sacral Neuromodulation Technology
Company awarded seven additional patents in Western Europe, Japan, China, Australia, and Canada.Business Wire 02.05.20
-
Health Canada Approves Full-Body MRI Labeling for the Axonics Sacral Neuromodulation System
Axonics previously received Health Canada approval for its complete r-SNM System and related system components in January 2017.Business Wire 01.22.20
-
Neurological
FDA Approves Axonics' Enhanced Neurostimulator Programmer
New programmer offers a fully wireless system that reduces time during surgery and simplifies post-implant device programming.Business Wire 01.21.20
-
Neurological
First U.S. Patient Implanted With Axonics' Sacral Neuromodulation System
The Axonics r-SNM System is approximately the size of a USB stick and is qualified to operate for at least 15 years.Businesswire 12.12.19
-
Neurological
FDA Approves Axonics' Sacral Neuromodulation for Urinary Indications
The Axonics r-SNM System was approved to treat overactive bladder (OAB) and urinary retention.Business Wire 11.14.19
-
FDA Approves Axonics' Sacral Neuromodulation System
The approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans.Business Wire 10.21.19
-
Axonics Announces One-Year Clinical Results from its ARTISAN-SNM Pivotal Study
Data show patients implanted with the Axonics r-SNM System receive significant improvements in urinary urgency incontinence symptoms and quality of life.Business Wire 09.26.19
-
FDA Approves Use of Full-Body MRI for Pivotal Study Patients Implanted With Axonics System
The approval was a result of a supplement filed by Axonics with the FDA under an IDE.Business Wire 08.05.19
-
Axonics Appoints Two New Members to its Board
The latest additions worked for J&J and Salter Labs.Business Wire 05.23.19
-
Axonics Granted Expanded CE Mark Label for 1.5T and 3T Full-Body MRI
Company submitted complete test data to the FDA gaining conditional Full Body MRI labeling approval in the U.S.Business Wire 04.05.19
-
Axonics Granted Seven U.S. Utility Patents for its Implantable Sacral Neuromodulation Technology
The patents issued range in subject matter and include coverage of the Axonics clinician programmer, patient remote control, and internal system electronics.Business Wire 01.04.19
-
Axonics Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Company is currently conducting a 129-patient pivotal clinical study for urinary incontinence patients.Business Wire 12.20.18
-
Axonics Receives CE Mark for its Sacral Neuromodulation External Trial System
System is an additional element of the Axonics r-SNM platform.Business Wire 08.13.18
-
Axonics Completes Enrollment of FDA Pivotal Study for its Sacral Neuromodulation System
Patients were implanted at 14 U.S. centers and five centers in Belgium, the Netherlands, U.K., and France.Business Wire 08.07.18
-
Axonics Sacral Neuromodulation System Receives Marketing Approval in Australia
Over 5 million people, or approximately 20 percent of Australians, experience bladder or bowel control problems.Axonics Modulation Technologies Inc. 02.06.18
-
First Patients Implanted With Axonics Sacral Neuromodulation System in FDA Pivotal Study
The device has been implanted in 11 patients under treatment at centers in the United States and Western Europe.Business Wire 01.25.18
-
Axonics Modulation Technologies Granted Seven New U.S. Patents
Newest patents are related to the company's implantable sacral neuromodulation technology.Business Wire 01.03.18
